| Metric | Q3'25 | Q4'25 | Change |
|---|---|---|---|
| Revenue | $4.10B (+5.2% YoY) | $4.34B (+10.3% YoY) | +540 bps acceleration |
| Adj. EBITDA | $949M (+1.1% YoY) | $1.046B (+5.0% YoY) | +390 bps acceleration |
| R&DS Net Bookings | $2.60B (+13% YoY) | $2.70B (+7% YoY) | -600 bps deceleration |
| R&DS Backlog Growth | 4.1% YoY | 5.3% YoY | +120 bps improvement |
| Book-to-Bill Ratio | 1.15x | 1.18x | +3 pts improvement |
| TAS Revenue | $1.631B (+5.0% reported) | $1.821B (+9.8% reported) | +480 bps acceleration |
| R&DS Revenue | $2.260B (+4.5% reported) | $2.330B (+9.1% reported) | +460 bps acceleration |
| CSMS Revenue | $209M (+16.1% reported) | $210M (+18.6% reported) | +250 bps acceleration |
| Free Cash Flow | $772M (record quarterly) | $561M | -$211M decline |
| Net Leverage | 3.52x | 3.63x | +11 bps deterioration |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.